104 related articles for article (PubMed ID: 20398027)
1. Anti-TNF therapy restores the hypothalamic-pituitary-adrenal axis.
Atzeni F; Straub RH; Cutolo M; Sarzi-Puttini P
Ann N Y Acad Sci; 2010 Apr; 1193():179-81. PubMed ID: 20398027
[TBL] [Abstract][Full Text] [Related]
2. Long-term anti-tumor necrosis factor antibody therapy in rheumatoid arthritis patients sensitizes the pituitary gland and favors adrenal androgen secretion.
Straub RH; Pongratz G; Schölmerich J; Kees F; Schaible TF; Antoni C; Kalden JR; Lorenz HM
Arthritis Rheum; 2003 Jun; 48(6):1504-12. PubMed ID: 12794817
[TBL] [Abstract][Full Text] [Related]
3. Psoriatic arthritis: clinical improvement and correlation with hormone axes in etanercept-treated patients.
Atzeni F; Straub RH; Cutolo M; Sarzi-Puttini P
Ann N Y Acad Sci; 2010 Apr; 1193():176-8. PubMed ID: 20398026
[TBL] [Abstract][Full Text] [Related]
4. Increased DHEAS levels in patients with rheumatoid arthritis after treatment with tumor necrosis factor antagonists: evidence for improved adrenal function.
Ernestam S; Hafström I; Werner S; Carlström K; Tengstrand B
J Rheumatol; 2007 Jul; 34(7):1451-8. PubMed ID: 17477470
[TBL] [Abstract][Full Text] [Related]
5. Hypothalamic-pituitary-adrenal-glucocorticoid axis function in rheumatoid arthritis.
Masi AT; Chrousos GP
J Rheumatol; 1996 Apr; 23(4):577-81. PubMed ID: 8730107
[No Abstract] [Full Text] [Related]
6. The neuroendocrine system and rheumatoid arthritis: insights from anti-tumor necrosis factor-alpha therapy.
Sternberg EM; Silverman MN; Cizza G
J Rheumatol; 2007 Jul; 34(7):1443-5. PubMed ID: 17611960
[No Abstract] [Full Text] [Related]
7. Hypothalamic-pituitary-adrenal axis impairment in the pathogenesis of rheumatoid arthritis and polymyalgia rheumatica.
Cutolo M; Foppiani L; Minuto F
J Endocrinol Invest; 2002; 25(10 Suppl):19-23. PubMed ID: 12508908
[TBL] [Abstract][Full Text] [Related]
8. Corticosteroids, a review.
Melillo N; Corrado A; Quarta L; Cantatore FP
Panminerva Med; 2007 Mar; 49(1):29-33. PubMed ID: 17468731
[TBL] [Abstract][Full Text] [Related]
9. Corticosteroid-induced suppression of the hypothalamo-pituitary-adrenal axis: observations on patients given oral corticosteroids for rheumatoid arthritis.
Jasani MK; Boyle JA; Greig WR; Dalakos TG; Browning MC; Thompson A; Buchanan WW
Q J Med; 1967 Jul; 36(143):261-76. PubMed ID: 6049762
[No Abstract] [Full Text] [Related]
10. The hypothalamic-pituitary-adrenal axis in asthmatic children.
Priftis KN; Papadimitriou A; Nicolaidou P; Chrousos GP
Trends Endocrinol Metab; 2008 Jan; 19(1):32-8. PubMed ID: 18155557
[TBL] [Abstract][Full Text] [Related]
11. [Hypothalamo-hypophyseal-adrenal function in rheumatoid arthritis treated with low-doses of corticoids].
Belmonte Serrano MA; Roig Escofet D; Gómez Sáez JM; Bonnín Lafuente MR
Med Clin (Barc); 1986 Sep; 87(7):275-9. PubMed ID: 3762252
[No Abstract] [Full Text] [Related]
12. Endotoxin and the hypothalamo-pituitary-adrenal (HPA) axis.
Beishuizen A; Thijs LG
J Endotoxin Res; 2003; 9(1):3-24. PubMed ID: 12691614
[TBL] [Abstract][Full Text] [Related]
13. The role of the endocannabinoid system in the regulation of hypothalamic-pituitary-adrenal axis activity.
Cota D
J Neuroendocrinol; 2008 May; 20 Suppl 1():35-8. PubMed ID: 18426497
[TBL] [Abstract][Full Text] [Related]
14. Involvement of the hypothalamic--pituitary--adrenal/gonadal axis and the peripheral nervous system in rheumatoid arthritis: viewpoint based on a systemic pathogenetic role.
Straub RH; Cutolo M
Arthritis Rheum; 2001 Mar; 44(3):493-507. PubMed ID: 11263762
[TBL] [Abstract][Full Text] [Related]
15. The effect of therapeutic glucocorticoids on the adrenal response in a randomized controlled trial in patients with rheumatoid arthritis.
Kirwan JR; Hickey SH; Hällgren R; Mielants H; Björck E; Persson T; Wollheim FA
Arthritis Rheum; 2006 May; 54(5):1415-21. PubMed ID: 16645969
[TBL] [Abstract][Full Text] [Related]
16. Effects of psychotropic medications on hypothalamic-pituitary-adrenal regulation.
Meador-Woodruff JH; Greden JF
Endocrinol Metab Clin North Am; 1988 Mar; 17(1):225-34. PubMed ID: 2897911
[TBL] [Abstract][Full Text] [Related]
17. Tumor necrosis factor-neutralizing therapies improve altered hormone axes: an alternative mode of antiinflammatory action.
Straub RH; Härle P; Sarzi-Puttini P; Cutolo M
Arthritis Rheum; 2006 Jul; 54(7):2039-46. PubMed ID: 16802339
[No Abstract] [Full Text] [Related]
18. Corticotropin releasing hormone and the hypothalamic-pituitary-adrenal axis in the regulation of inflammatory arthritis.
Wilder RL
Agents Actions Suppl; 1993; 41():3-9. PubMed ID: 8317340
[TBL] [Abstract][Full Text] [Related]
19. Protective effects of endotoxin in a rat model of chronic inflammation are accompanied by suppressed secretion of pro-inflammatory cytokines and biphasic alteration in hypothalamo-pituitary-adrenal axis activity.
Richards LJ; Chover-Gonzalez A; Harbuz MS; Jessop DS
J Neuroendocrinol; 2006 Nov; 18(11):875-82. PubMed ID: 17026537
[TBL] [Abstract][Full Text] [Related]
20. Opioid endocrinopathy: a clinical problem in patients with chronic pain and long-term oral opioid treatment.
Rhodin A; Stridsberg M; Gordh T
Clin J Pain; 2010 Jun; 26(5):374-80. PubMed ID: 20473043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
